Vilanterol and Umeclidinium Bromide
Phase 3Small molecule
Vilanterol and Umeclidinium Bromide is one of 40 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Lunsekimig
SanofiPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Tozorakimab
AstraZenecaPhase 3
Astegolimab
RochePhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
Avinza
HHikma Pharmaceuticals LLC
Phase 2
Vilanterol and Umeclidinium Bromide
SSamsung Medical Center
Phase 3
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSamsung Medical Center